|KCR||Topography Code (ICD-O) (Topography)||30080||yes|
Field Length: 5
Enter the ICD-O 3rd edition Topography code which describes the anatomical site of the patient's primary tumor. This is a five character field. After the "C", enter the three digit code; the decimal point is already in the correct position.
The International Classification of Diseases for Oncology (ICD-O) 3rd edition, represents an extension of Chapter II of the ICD-10 coding reference. ICD-O permits the coding of all neoplasms by topography, morphology, and cell behavior -- providing greater detail than that permitted with ICD-9 or ICD-10 coding schemes.
The structure of the ICD-O reference book contains three major sections:
Topography - A numerical list of anatomic sites adapted from the malignant neoplasms section of Chapter II of ICD-10. The topographic terms have 3-digit code numbers preceded by a "C" which run from C00.0 to C80.9.
Morphology - A numerical list of histologic terms that is a revised and expanded version of the morphology section of The Manual of Tumor Nomenclature and Coding. The ICD-O, 3rd edition includes new histologic types that have come into the literature since 1990. It has revised the Leukemia and Lymphoma sections and now includes several hematopoietic diseases that were previously considered borderline.
Alphabetic Index - A list of anatomic sites, histologic terms and selected tumor-like lesions and conditions.
Resources for Coding Primary Site for Solid Tumors, in priority order
1. Refer to the introductory pages of the International Classification of Diseases for Oncology, 3rd edition, for a more detailed discussion of the differences between ICD-O and ICD-10, as well as for rules governing the appropriate assignment of ICD-O codes. See also APPENDIX J for errata and clarifications to ICD-O-3rd edition.
a. Including Coding Guidelines in Appendix C
Coding Instructions for Solid Tumors
See the Coding Guidelines for Topography and Morphology in the introduction of the ICD-O-3 for additional details. Refer also to the current Solid Tumor Rules for selected primary site coding instructions.
1. Unless otherwise instructed, use all available information in the medical record to code the site
2. Code the site in which the primary tumor originated, even if it extends onto/into an adjacent subsite
a. Primary site should always be coded to reflect the site of origin according to the medical opinion on the case. Look for information about where the neoplasm originated. Always code the primary site based on where the tumor arose / site of origin.
b. Site of origin may be indicated by terms such as "tumor arose from…," "tumor originated in…," or similar statements
c. Site of origin is not necessarily the site of a biopsy
d. Tumors may involve many sites. The primary site code should reflect the site where the tumor arose rather than all of the sites of involvement.
Example 1: Final diagnosis is adenocarcinoma of the upper lobe of the right lung. Code the topography to lung, upper lobe (C341).
Example 2: The patient has a 4 cm tumor in the right breast. The tumor originated in the upper inner quadrant and extends into the lower inner quadrant. Code the primary site to upper inner quadrant of breast (C502).
Example 3: Patient has a right branchial cleft cyst; the pathology report identifies an adenocarcinoma arising in an ectopic focus of thyroid tissue within the branchial cleft cyst. Thyroidectomy pathology is negative. Code the primary site to branchial cleft (C104).
Example 4: The patient had a total hysterectomy with a bilateral salpingo-oophorectomy ten years ago for non-cancer reasons. She now has widespread cystadenocarcinoma in the peritoneum. Code the primary site to peritoneum, NOS (C482). (The chart may or may not state that the patient has extra-ovarian carcinoma.)
Example 5: Pathology report shows adenocarcinoma arising in a patch of endometriosis on the sigmoid colon. Code the primary site to sigmoid colon (C187), the site in which the cancer originated.
Example 6: The patient has a left lower lip wedge excision showing invasive squamous cell carcinoma at the mucocutaneous junction. There is no further information in operative report or pathology report regarding the location of this tumor that would indicate this is a skin primary. Assign C001, external lower lip. C001 includes vermilion border of lower lip. Vermilion border is synonymous with mucocutaneous junction.
3. Do not adjust the primary site code to fit staging or any other data items
4. Code the last digit of the primary site code to ‘8’ when a single tumor overlaps an adjacent subsite(s) of an organ and the point of origin cannot be determined
Example: The patient has a primary tumor of the cervicothoracic esophagus and the point of origin is unknown. Code the primary site to C158.
Note: Skin cancers overlapping sites in the head and neck ONLY.
Assign the primary site code for the site where the bulk of the tumor is or where the epicenter is; do not use code C448.
5. Code the site of the invasive tumor when there is an invasive tumor and also in situ tumor in different subsites of the same anatomic site
Example 1: Patient has an invasive breast tumor in the upper-outer quadrant of the left breast and in situ tumor in multiple quadrants of the left breast. Code the primary site to C504 (upper outer quadrant of breast).
Example 2: Patient has in situ Paget disease of the right nipple and invasive duct carcinoma of the lower inner quadrant of the right breast. Code the primary site to C503 (lower inner quadrant).
6. Code the last digit of the primary site code to ‘9’ for single primaries, when multiple tumors arise in different subsites of the same anatomic site and the point of origin cannot be determined
Example 1: During a transurethral resection of the bladder (TURB), the physician describes multiple papillary tumors in the bladder neck (C675) and the lateral wall of the bladder (C672). Code the primary site as bladder, NOS (C679).
Example 2: Patient has an infiltrating duct tumor in the upper outer quadrant (C504) of the right breast and another infiltrating duct carcinoma in the lower inner (C503) quadrant of the right breast. Code the primary site as breast, NOS (C509).
7. Some histology/behavior terms in ICD-O-3.2 have a related site code in parentheses; for example, hepatoma (C220)
a. Code the site as documented in the medical record and ignore the suggested ICD-O-3.2 code when a primary site is specified in the medical record
Example: The path report says “infiltrating duct carcinoma of the head of pancreas.” The listing in ICD-O-3.2 is infiltrating duct carcinoma 8500/3 (C50_). Code the primary site to head of pancreas (C250), NOT to breast (C50_) as suggested by the ICD-O-3.2.
b. Use the site code suggested by ICD-O-3.2 when the primary site is the same as the site code suggested or the primary site is unknown
Example 1: The biopsy is positive for hepatoma, and no information is available about the primary site. Code the primary site to liver (C220) as suggested by ICD-O-3.2.
Example 2: Excision of the right axillary nodes reveals metastatic infiltrating duct carcinoma. The right breast is negative. ICD-O-3.2 shows infiltrating duct carcinoma (8500) with a suggested site of breast (C50_). Code the primary site as breast, NOS (C509).
c. Use the site code suggested by ICD-O-3.2 when there is no information available indicating a different primary site
Example: Biopsy of lymph node diagnosed as metastatic non-small cell carcinoma. Patient expired and there is no information available about the primary site. Assign C349 based on the site code suggested in ICD-O-3.2.
8. Code the primary site, not the metastatic site. If a tumor is metastatic and the primary site is unknown, code the primary site as unknown (C809).
a. Code primary site using results of the molecular test CancerTYPE ID only when there is no other information about the primary site. Document in the text that the site is solely based on results from CancerTYPE ID molecular testing.
Note: CancerTYPE ID tests are a standardized molecular method of determining primary site in tumors initially identified in a metastatic site. The use of CancerTYPE ID to determine primary site is not yet a standard practice and has not received FDA clearance.
9. See the site-specific coding guidelines in SEER Appendix C for primary site coding guidelines for the following sites:
|Brain/CNS, Benign and Borderline||Kaposi Sarcoma of All Sites|
10. See section below for primary site coding guidelines for sarcoma
a. Code C422 (spleen) as the primary site for angiosarcoma of spleen
b. Code C50_ (breast) for angiosarcoma of breast. Although angiosarcoma actually originates in the lining of the blood vessels, an angiosarcoma originating in the breast has a poorer prognosis than many other breast tumors.
12. Gastrointestinal Stromal Tumors (GIST): Code the primary site to the location where the GIST originated
a. Code the primary site to the location of the transplanted organ when a malignancy arises in a transplanted organ, i.e., code the primary site to where the malignancy resides or lies
Example: There is a diagnosis of malignancy in transplanted section of colon serving as esophagus. Code the primary site as esophagus. Document the situation in a text field.
b. For additional information about hematopoietic-related transplants, refer to the Hematopoietic and Lymphoid Neoplasm Coding Manual and Database.
14. Assign primary site code C449, skin NOS, for a Merkel cell carcinoma presenting in a nodal or distant metastatic site and site of origin is unknown
15. In the absence of any additional information about the primary site, assign the codes listed for these primary sites/histologies
Angle of the stomach
Angular incisura of stomach
Back of tongue
Book-leaf lesion (mouth)
Colored / lipstick portion of upper lip
Edge of tongue
Gastric angular notch (incisura)
Genu of pancreas
Incisura, incisura angularis
Infrahilar area of lung
Interhemispheric fissure (cerebrum)
Nail bed, thumb
Perihilar bile duct
Prostatic sinus (urethra)
Testis, descended post orchiopexy
True vocal folds
Uncinate of pancreas
16. When the medical record does not contain enough information to assign a primary
a. Consult a physician advisor to assign the site code
b. Use the NOS category for the organ system or the Ill-Defined Sites (C760-C768) if the physician advisor cannot identify a primary site
c. Occult Tumors of the Head and Neck
i. Assign primary site C119 (nasopharynx) for occult head and neck tumors with
cervical lymph node metastasis in Levels I-VII, and other group lymph nodes
positive for Epstein–Barr virus (EBV+) (regardless of p16 status) encoded small
RNAs (EBER) identified by in situ hybridization
ii. Assign primary site C109 (oropharynx) for occult head and neck tumors with
cervical lymph node metastasis in Levels I-VII, and other group lymph nodes, p16
positive with histology consistent with HPV-mediated oropharyngeal carcinoma
iii. Assign C760 for Occult Head and Neck primaries with positive cervical lymph
nodes. Schema Discriminator 1: Occult Head and Neck Lymph Nodes is used to
discriminate between these cases and other uses of C760
For more information about schemas and schema IDs, go to the SSDI Manual, Appendix A.
d. Assign the NOS code for the body system when there are two or more possible primary sites documented and all are within the same system
Example: Two possible sites are documented in the GI system such as colon and small intestine; code to the GI tract, NOS (C269). Document the possible primary sites in a text field.
e. Code unknown primary site when there is a physician statement of unknown primary site ONLY when none of the above instructions can be applied
f. Code Unknown Primary Site (C809) if there is not enough information to assign an NOS or Ill-Defined Site category
The majority of sarcomas arise in mesenchymal or connective tissues that are located in the musculoskeletal system, which includes the fat, muscles, blood vessels, deep skin tissues, nerves, bones, and cartilage. The default code for sarcomas of unknown primary site is C499 rather than C809.
Sarcomas may also arise in the walls of hollow organs and in the viscera covering an organ. Code the primary site to the organ of origin.
Example 1: The pathology identifies a carcinosarcoma of the uterine corpus. Code the primary site to corpus uteri (C549).
Example 2: Rhabdomyosarcoma of ethmoid sinus. Code primary site to C311.
Code the organ of origin as the primary site when leiomyosarcoma arises in an organ. Do not code soft tissue as the primary site in this situation.
Example 1: Leiomyosarcoma arises in kidney. Code the primary site to kidney (C649).
Example 2: Leiomyosarcoma arises in prostate. Code primary site to prostate (C619).
Coding Instructions for Hematopoietic and Lymphoid Neoplasms (9590/3-9993/3)
See the Hematopoietic and Lymphoid Neoplasm Coding Manual and Database for instructions on coding the primary site for hematopoietic and lymphoid neoplasms.